Overview

Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors

Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
To evaluate the tolerability and safety of ONO-7475 monotherapy and combinations with ONO-4538 in patients with advanced or metastatic solid tumors
Phase:
Phase 1
Details
Lead Sponsor:
Ono Pharmaceutical Co. Ltd
Treatments:
Antibodies, Monoclonal
Nivolumab